Anti-depressants

You are currently browsing articles tagged Anti-depressants.

Conventional wisdom holds that physicians can use anti-depressants to treat long term depression.  Many patients, however, spend years or even decades taking these drugs.  Is this how the inventors of anti-depressants believe they would be used?

Author Robert Whitaker believes not:

You find that even with major depression, in the pre-antidepressant era – and this is depression so severe people were hospitalized – they could expect to get better. The episode would eventually pass.

… So when antidepressants were introduced, the thought was okay, we really can hope to improve on this sort of natural recovery, but maybe we can help people recover quicker? So that really was the rationale for the use of antidepressants.

But it’s really interesting if you follow this course through, forward in history. The minute they start using antidepressants in any sort of large numbers, doctors start saying, “Well, you know, my patients may be getting better, the depression maybe lifting faster, but then we’re noticing that they’re also relapsing more frequently than before, back into depression.”

So right away you get this question: Does the drug treatment actually put people on a more chronic course than before?”

This reminds me of government “temporary” spending programs.  In times of fiscal crisis, the government often institutes temporary spending packages to revive the economy (e.g., the Stimulus Bill or ARRA).  Although these actions may help revive the economy in the short run, in the long run they often lead to reduced growth prospects.  Oftentimes, however, as the status quo changes, entrenched interests make it difficult to repeal a bill.

Similarly, giving someone anti-depressants changes the status quo from one of a non-drug user to a drug user.  Physicians become accustomed to treating the patient with drugs and many believe it stabilizes the patient.  Further, the patient often experiences withdrawal symptoms if they attempt to change their status quo from that of a user to a non-user.

Mr. Whitaker also cites a Duke University study from the 1990s examining 3 patient groups: 1) Exercise only 2) Exercise plus antidepressant 3) Antidepressant only.

After six weeks, the drug-only group was doing slightly better than the other two groups. However, after 10 months of follow-up, it was the exercise-only group that had the highest remission and stay-well rate.

Both anti-depressants and stimulus packages offer short run relief for the patient or economy.  Excessive use of these short run measures, however, leads to worse outcomes in the long run.

Tags: ,

Randomized clinical trials (RCTs) are the “gold standard” for medical studies. Nevertheless, even RCTs have their problems. An NBER working paper by Ludwig, Marcotte and Norberg points highlights some of these issues. The authors examine whether or not anti-depressants reduce suicide rates (they find that anti-depressants do reduce suicide rates).

Unfortunately, using data from RCTs will not give an accurate picture of an anti-depressant’s impact on suicide. For one, RCTs have relatively small sample sizes due to their expense. Since suicide occurs very infrequently, it will be difficult to pick up an statistically significant differences in suicide rates between the treatment and control groups. Secondly, people at high risk for suicide will likely be excluded from the RCT for ethical reasons. Thus, the RCT may have a sample which will under-represent individuals with suicidal tendencies.

Tags: , ,